Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Oral minoxidil may slow male pattern baldness and cause body hair growth, but hair loss can happen after stopping it.

This study found that the ENERGI-F701 solution significantly increased hair density and reduced hair shedding in women with female pattern hair loss, with fewer local skin reactions compared to Regaine® 2% minoxidil, suggesting its effectiveness and safety as a treatment option.

This study found that 78% of patients continued taking oral minoxidil for androgenetic or traction alopecia, with 33% reporting decreased hair shedding and 28% noting increased scalp hair.

This article reviews the triggers, diagnosis, and management of telogen effluvium in men and women, emphasizing the role of patient education and reassurance, but presents no new clinical findings.

This study found that using very-low-dose oral minoxidil (0.25 mg/d) led to improvement or stabilization of hair parameters in 40% to 60% of men with androgenetic alopecia, although results were not statistically significant for the overall group.

Oral minoxidil may improve hair loss in men and women, but has some side effects.

This study found that using topical minoxidil did not affect the percentage of hair survival after transplantation for androgenetic alopecia, but did reduce initial postoperative hair shedding in 60% of grafts.

In this study, oral minoxidil treatment significantly increased serum VEGF levels and improved hair growth measures compared to a control group, suggesting its potential as an effective approach for promoting hair regrowth in androgenetic alopecia.

Oral minoxidil effectively reduces hair shedding in women with chronic telogen effluvium.

This study reports a 10-year-old boy with ectodermal dysplasia and progressive balding experienced reduced hair shedding and increased hair density after four months of sublingual minoxidil treatment, without side-effects.

Low-dose oral minoxidil is a promising, safe treatment for various hair diseases, improving hair thickness and density, but more research is needed on long-term side effects and treatment duration.

This letter discusses the limited adaptation of low dose oral minoxidil for androgenetic alopecia in North America and reports no new clinical results; the authors suggest safety concerns or unclear dosing may be factors.

This study suggests that hair shedding, often reported with minoxidil use, is poorly defined in androgenetic alopecia treatment despite its prevalence on social media, highlighting a gap in the literature.

This systematic review found that both oral and topical minoxidil have similar efficacy in improving hair density and terminal hair density among patients with androgenetic alopecia, suggesting that oral minoxidil may be a viable second-line or adjunct treatment option.

This article discusses the historic use of oral minoxidil for severe hypertension and the subsequent development of a topical formulation for treating pattern hair loss, but reports no new results.

This review suggests that low-dose oral minoxidil may enhance hair density in certain nonandrogenetic alopecias, but highlights the need for controlled trials due to mixed and limited evidence.

This review examines chronic telogen effluvium, highlighting its distinctive features and the need for reassurance about its non-progressive nature, but reports no new clinical results.

This study found that a combination of 5% hexane extract of Curcuma aeruginosa and 5% minoxidil slowed hair loss and increased hair growth in men with androgenetic alopecia.

This article reviews common causes of hair loss, noting that a well-directed history and examination are often sufficient for diagnosis, and reports no new clinical findings.

This article discusses the potential for topical caffeine as a natural alternative for treating androgenetic alopecia due to its ability to penetrate skin, but it reports no new clinical findings.

This article is a letter to the editor discussing hair graying and loss potentially induced by imatinib mesylate, but it does not provide new research results.

In this report, a 44-year-old woman with female pattern alopecia experienced significant hair regrowth after 3.5 months of oral finasteride, with no side effects, after not responding to topical minoxidil.

COVID-19 and related stress may increase hair loss known as Telogen effluvium.

This review discusses recent advances in hair follicle research, highlighting therapeutic and cosmetic applications, but reports no new study results.

This review discusses telogen effluvium as a common cause of diffuse hair loss and reports no new clinical results, noting diagnostic and treatment challenges.

This study found that watching educational videos from a social media video library significantly improved patients' knowledge of hair loss disorders.

This review discusses different types of hair loss, their potential causes, and advances in treatments, and reports no new clinical findings.

Many new moms lose hair after childbirth due to hormonal changes, but it usually grows back within a year.

This article reviews drug-induced alopecia, its diagnosis, and treatments, but presents no new clinical findings.

Bicalutamide may reduce hair shedding in women but needs longer trials to confirm its effectiveness.